Credit Suisse Maintains Their Hold Rating on Bristol Myers (BMY)

In a report released today, Vamil Divan from Credit Suisse maintained a Hold rating on Bristol Myers (BMY), with a price target of $59. The company’s shares opened today at $51.67.

According to, Divan is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.1% and a 40.7% success rate. Divan covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Aimmune Therapeutics, and Johnson & Johnson.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bristol Myers with a $56.50 average price target, a 9.3% upside from current levels. In a report issued on February 11, Guggenheim also maintained a Hold rating on the stock.

See today’s analyst top recommended stocks >>

Based on Bristol Myers’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.97 billion and net profit of $1.19 billion. In comparison, last year the company earned revenue of $5.45 billion and had a GAAP net loss of $2.33 billion.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts